GSK 6-K 2025 - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Emma Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 January 2025<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Volume(s)
			898
			1,492
			1,686
d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	4,076<br><br> <br><br><br>13.4950
e)	Date<br>of the transaction	2025-01-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	American Depositary Shares ('ADSs')<br><br><br><br><br><br>ISIN: US37733W2044
b)	Nature<br>of the transaction	Increase in notional interest in ADSs following the re-investment<br>of dividends paid to shareholders on 9 January 2025 on ADSs held in<br>the Company's Deferred Annual Bonus Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			$33.7500	495
d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br><br><br><br><br>Price
e)	Date<br>of the transaction	2025-01-14
f)	Place<br>of the transaction	New York Stock Exchange (XNYS)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 January 2025<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£13.4950	643
d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br><br><br><br><br>Price
e)	Date<br>of the transaction	2025-01-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 January 2025<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Volume(s)
			141
			272
			425
d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	838<br><br> <br><br><br>13.4950
e)	Date<br>of the transaction	2025-01-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 January 2025<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Volume(s)
			174
			264
			430
d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	868<br><br> <br><br><br>13.4950
e)	Date<br>of the transaction	2025-01-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Sally Jackson
b)	Position/status	SVP, Global Communications and CEO Office
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 January 2025<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Volume(s)
			81
			164
			267
d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	512<br><br> <br><br><br>13.4950
e)	Date<br>of the transaction	2025-01-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Luke Miels
b)	Position/status	Chief Commercial Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 January 2025<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Volume(s)
			295
			801
			636
d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	1,732<br><br> <br><br><br>13.4950
e)	Date<br>of the transaction	2025-01-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Shobie<br>Ramakrishnan
b)	Position/status	Chief<br>Digital and Technology Officer
c)	Initial<br>notification/amendment	Initial<br>notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK<br>plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	American<br>Depositary Shares ('ADSs') <br><br> <br><br>ISIN: US37733W2044
b)	Nature<br>of the transaction	Increase<br>in notional interest in ADSs following the re-investment of<br>dividends paid to shareholders on 9 January 2025 on ADSs held in<br>the Company's Deferred Annual Bonus Plan
c)	Price(s)<br>and volume(s)		Volume(s)
			130
			203
			30
d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	363<br><br> <br><br><br>33.7500
e)	Date<br>of the transaction	2025-01-14
f)	Place<br>of the transaction	New York Stock Exchange (XNYS)

All values are in US Dollars.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 January 2025<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Volume(s)
			368
			196
			510
d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	1,074<br><br> <br><br><br>13.4950
e)	Date<br>of the transaction	2025-01-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 January 2025<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Volume(s)
			178
			295
			614
d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	1,087<br><br> <br><br><br>13.4950
e)	Date<br>of the transaction	2025-01-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 January 2025<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Volume(s)
			123
			193
			343
d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	659<br><br> <br><br><br>13.4950
e)	Date<br>of the transaction	2025-01-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase<br>in notional interest in Ordinary Shares following the re-investment<br>of dividends paid to shareholders on 9 January 2025 on Ordinary<br>Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Volume(s)
			471
			531
			130
d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	1,132<br><br> <br><br><br>13.4950
e)	Date<br>of the transaction	2025-01-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 January 2025<br>on Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Volume(s)
			223
			654
d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	877<br><br> <br><br><br>13.4950
e)	Date<br>of the transaction	2025-01-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Emma Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63
b)	Nature of<br>the transaction	Acquisition of Ordinary Shares following the re-investment of<br>dividends paid to shareholders on 9 January 2025 on Ordinary Shares<br>held in the Company's Performance Share Plan subject to a 2-year<br>holding period
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£13.4950	8001.047
d)	Aggregated<br>information<br><br><br><br><br><br>Aggregated volume<br><br><br><br><br><br>Price	N/A (single transaction)
e)	Date<br>of the transaction	2025-01-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	American Depositary Shares ('ADSs')<br><br><br><br><br><br>ISIN: US37733W2044
b)	Nature<br>of the transaction	Acquisition of ADSs following the re-investment of dividends paid<br>to shareholders on 9 January 2025
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			$32.1317	3445.486
d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br><br><br><br><br>Price
e)	Date<br>of the transaction	2025-01-14
f)	Place<br>of the transaction	New York Stock Exchange (XNYS)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	American Depositary Shares ('ADSs')<br><br><br><br><br><br>ISIN: US37733W2044
b)	Nature<br>of the transaction	Acquisition of ADSs following the re-investment of dividends paid<br>to shareholders on 9 January 2025
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			$32.1317	371.810
d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br><br><br><br><br>Price
e)	Date<br>of the transaction	2025-01-14
f)	Place<br>of the transaction	New York Stock Exchange (XNYS)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---
a)	Name	Shobie Ramakrishnan
b)	Position/status	Chief Digital and Technology Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	American Depositary Shares ('ADSs')<br><br><br><br><br><br>ISIN: US37733W2044
b)	Nature<br>of the transaction	Acquisition of ADSs following the re-investment of dividends paid<br>to shareholders on 9 January 2025
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			$32.1317	183.525
d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br><br><br><br><br>Price
e)	Date<br>of the transaction	2025-01-14
f)	Place<br>of the transaction	New York Stock Exchange (XNYS)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)
Date: January<br>15, 2025
	By:/s/ VICTORIA<br>WHYTE<br><br><br>--------------------------
	Victoria Whyte
	Authorised<br>Signatory for and on
	behalf<br>of GSK plc